BioNTech registers Phase 1 HIV vaccine trial with an analytical treatment interruption
BNT168 will be tested in people with and without HIV, including a supervised pause in antiretroviral therapy to gauge immune control of the virus.
Executive Summary
- BioNTech has registered a new Phase 1 trial for its RNA-based HIV vaccine candidate, set to test safety and immune response in adults living with and without the virus.
- The protocol goes beyond a standard safety study by pausing antiretroviral therapy under monitoring in participants living with HIV, aiming to measure whether the vaccine can help control the virus without daily treatment.
- The HIV vaccine field is sparse and has moved slowly for years, and an RNA-based approach here would extend BioNTech's platform into a therapeutic setting distinct from its prophylactic vaccine work.
- The trial has not yet started recruiting and will not reach its primary completion until 2028, putting any read on immune control years away.
The trial
The study, registered as NCT07698600, plans to enroll 126 adults age 18 to 50, split between people living with HIV (PLWH) and people living without HIV (PLWOH). It is listed as not yet recruiting, with a start date of July 1, 2026, and a primary completion date of January 1, 2028. The primary endpoints are all safety measures: the occurrence of at least one adverse event, one adverse event of special interest, one serious adverse event, and solicited local and systemic reactions after each dose, tracked separately by cohort and against pooled placebo. NCT07698600A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIVNCT07698600
The treatment-interruption design
For participants living with HIV, the trial layers on a set of secondary endpoints built around an analytical treatment interruption (ATI), a supervised pause in antiretroviral therapy (cART) to see if the immune system controls the virus alone. These measure the change and magnitude of CD4+ T cell counts from the start of the pause through cART restart, the time to loss of virologic control (viral load above 200 copies per mL), and the time to meeting criteria to restart treatment, tracked for up to 168 days after the pause begins. Eligible participants with HIV must have been on stable combination antiretroviral therapy for at least 12 months, with a CD4+ T cell count of at least 500 cells per microliter and viral load under 50 copies per mL for at least six months, and sites must be able to construct an active alternative regimen if the pause fails. That combination, a safety-first primary endpoint paired with a virologic-control secondary endpoint under a monitored treatment pause, signals BioNTech is testing for a functional immune-control signal, a harder bar than tolerability alone. NCT07698600A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIVNCT07698600
The field
One other active industry trial is currently testing the HIV target within HIV infection, and Phase 1 trials against this target-indication pair have a 6% termination rate, with 1 of 18 trials stopped early. Three prior trials have used RNA-based therapy in HIV infection, and BioNTech's own competing candidate here is not compared against a specified active comparator arm in the current registration. The nearest mechanism-sharing comparator identified is a Phase 2 polyvalent DNA HIV vaccine from Worcester HIV Vaccine, which targets HIV-1 Env rather than the same target definition used here, making it a mechanism neighbor rather than a direct comparator. No industry trial has yet reached a resolved outcome using an RNA-based vaccine against this specific target-indication pairing, leaving no same-modality precedent to benchmark this design against. NCT07698600A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIVNCT07698600
Sponsor context
BioNTech has completed 36 of its 47 globally tracked trials, a 77% completion rate, and this is the company's only trial currently in Not-yet-recruiting status. The sponsor's broader pipeline spans 81 trials across all statuses, with 21 currently recruiting and 11 terminated historically. This HIV program sits outside BioNTech's better-known prophylactic and oncology vaccine work, extending its RNA platform into a therapeutic immune-control application. NCT07698600A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIVNCT07698600
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.